PMID- 35070896
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240405
IS  - 2227-684X (Print)
IS  - 2227-8575 (Electronic)
IS  - 2227-684X (Linking)
VI  - 10
IP  - 12
DP  - 2021 Dec
TI  - Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for 
      HER2-positive locally advanced breast cancer: a retrospective case-series study.
PG  - 3362-3368
LID - 10.21037/gs-21-770 [doi]
AB  - BACKGROUND: The anti-tumor activity of pyrotinib has been confirmed in human 
      epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This 
      study investigated the effect of pyrotinib plus nab-paclitaxel, doxorubicin, and 
      cyclophosphamide as neoadjuvant therapy in patients with HER2-positive locally 
      advanced breast cancer. METHODS: In this single-center retrospective study, 
      female patients with HER2-positive locally advanced breast cancer received 
      pyrotinib 320 mg orally once a day and the TAC regimen (nab-paclitaxel 260 
      mg/m(2), liposomal doxorubicin 20 mg/m(2), and cyclophosphamide 600 mg/m(2)) on 
      day 1 of each 21-day cycle. Surgery was performed after 4-6 cycles of neoadjuvant 
      therapy. The outcomes included total pathological complete response (tpCR, 
      ypT0/Tis ypN0) rate, objective response rate (ORR) after neoadjuvant therapy, 
      progression-free survival, overall survival, and the incidence of adverse events 
      (AEs). RESULTS: Between March 2019 and January 2020, a total of 22 patients were 
      included. The median age was 48 years (range, 32-60). The ORR was 100% after the 
      completion of neoadjuvant therapy. Ten (45.5%) patients achieved tpCR, including 
      four of ten (40.0%) patients with positive hormone receptor, and six of 12 
      (50.0%) patients with negative hormone receptor. As at December 2020, no disease 
      recurrence, progression, or death occurred. All patients suffered AEs after 
      neoadjuvant therapy, most of which were grade 1-2. Grade >/=3 AEs included diarrhea 
      [4 (18.2%)], rash [2 (9.1%)], and hand-foot syndrome [1 (4.5%)]. CONCLUSIONS: 
      Neoadjuvant pyrotinib combined with the TAC regimen showed promising clinical 
      benefit in patients with HER2-positive locally advanced breast cancer, with an 
      acceptable safety profile.
CI  - 2021 Gland Surgery. All rights reserved.
FAU - Yao, De-Shun
AU  - Yao DS
AD  - Second Department of Breast Surgery, Tangshan People's Hospital, North China 
      University of Science and Technology, Tangshan, China.
FAU - Wang, Wei
AU  - Wang W
AD  - School of Clinical Medicine, North China University of Science and Technology, 
      Tangshan, China.
FAU - Chang, Jin-Yi
AU  - Chang JY
AD  - School of Clinical Medicine, North China University of Science and Technology, 
      Tangshan, China.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Second Department of Breast Surgery, Tangshan People's Hospital, North China 
      University of Science and Technology, Tangshan, China.
FAU - Zhang, Hui-Wen
AU  - Zhang HW
AD  - College of Nursing and Rehabilitation, North China University of Science and 
      Technology, Tangshan, China.
FAU - Xu, Jin-Xia
AU  - Xu JX
AD  - Nuclear Medicine Clinical Laboratory, Tangshan People's Hospital, North China 
      University of Science and Technology, Tangshan, China.
FAU - Cai, Hai-Feng
AU  - Cai HF
AD  - Second Department of Breast Surgery, Tangshan People's Hospital, North China 
      University of Science and Technology, Tangshan, China.
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Gland Surg
JT  - Gland surgery
JID - 101606638
PMC - PMC8749092
OTO - NOTNLM
OT  - Pyrotinib
OT  - breast cancer
OT  - chemotherapy
OT  - human epidermal growth factor receptor 2
OT  - neoadjuvant therapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/gs-21-770).
EDAT- 2022/01/25 06:00
MHDA- 2022/01/25 06:01
PMCR- 2021/12/01
CRDT- 2022/01/24 08:54
PHST- 2021/10/29 00:00 [received]
PHST- 2021/12/16 00:00 [accepted]
PHST- 2022/01/24 08:54 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/01/25 06:01 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
AID - gs-10-12-3362 [pii]
AID - 10.21037/gs-21-770 [doi]
PST - ppublish
SO  - Gland Surg. 2021 Dec;10(12):3362-3368. doi: 10.21037/gs-21-770.